首页 正文

Bortezomib-Cyclophosphamide-Dexamethasone versus Rituximab in PGNMID

{{output}}
Background: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a rare renal disorder for which prospective controlled treatment evidence is limited. Clone-directed therapies targeting plasma cell... ...